Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanogen/Epoch seal merger deal:

This article was originally published in Clinica

Executive Summary

Shareholders of Nanogen and Epoch Biosciences have given the thumbs up to a merger between the two companies. Under the agreement, Epoch stockholders will exchange each share of the Bothell, Washington-based molecular diagnostics firm for 0.4673 Nanogen shares. Based on Nanogen's closing price of $7.27 on December 14 (the day before the announcement), the total value of the transaction is estimated at $97m.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel